A Bay Area startup is harnessing the haute monoclonal antibody technology to develop treatment for psoriasis, cancers and inflammatory disease, and is likely about to kick off some serious late-stage efficacy trials.
AbGenomics is in the midst of a $24.5 million fundraising round, according to regulatory filings, and has raised $13.2 million to date. The company splits its time between the Bay Area, the Netherlands and Taiwan.
Its most advanced drug is its psoriasis treatment, which it has advanced through Phase II trials. It has three other antibody drug conjugates in the clinic, however – one targeting autoimmune disorders, one for advanced solid tumors and another for gastric and pancreatic cancers.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The psoriasis treatment, AbGn-168H, can specifically target late-stage activated T-cells to treat immune disorders that stretch beyond the skin condition, AbGenomics said. It can extend to Type I diabetes, multiple sclerosis and Crohn’s disease.
